8-K: Mangoceuticals Announces 1-for-15 Reverse Stock Split to Regain Nasdaq Compliance

Mangoceuticals, Inc. has announced a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective October 16, 2024.

Summary

• Mangoceuticals, Inc. has implemented a 1-for-15 reverse stock split of its common stock.
• The reverse stock split was approved by the company's stockholders on March 25, 2024, and the final ratio was set by the Board of Directors on October 7, 2024.
• The reverse stock split will be effective on October 16, 2024, at 12:01 a.m. Eastern Time.
• Trading on a post-split basis will begin on the Nasdaq Capital Market on October 16, 2024.
• The number of outstanding shares will be reduced from approximately 35.5 million to approximately 2.4 million.
• The company's trading symbol, MGRX, will remain unchanged.
• The primary reason for the reverse stock split is to meet Nasdaq's minimum bid price requirement of $1.00 per share for continued listing.
• The company received a deficiency letter from Nasdaq on October 30, 2023, for not meeting the minimum bid price requirement.
• The company was given until October 28, 2024, to regain compliance.
• The reverse stock split will also proportionately adjust stock options and other equity awards.

Sentiment

Score: 5

Explanation: The document is neutral, focusing on a necessary action to maintain listing compliance. While the reverse stock split is a negative indicator of past performance, it is a proactive step to address the issue. The document does not contain any positive or negative sentiment.

Positives

• The reverse stock split is a proactive measure to regain compliance with Nasdaq listing requirements.
• The company is taking steps to ensure continued listing on the Nasdaq Capital Market.
• The reverse stock split will not change the par value of the common stock or voting rights.
• Stockholders will receive whole shares in lieu of fractional shares.

Negatives

• The reverse stock split is a result of the company's stock price falling below the minimum bid price requirement.
• The reverse stock split will significantly reduce the number of outstanding shares.

Risks

• The company's ability to maintain the listing of its common stock on Nasdaq is not guaranteed.
• There is a risk that the reverse stock split may not be sufficient to maintain compliance with Nasdaq's minimum bid price requirement.
• The company faces risks related to its ability to commercialize its products and obtain regulatory approvals.
• The company is subject to risks associated with related party relationships and agreements.
• The company is subject to risks related to competition and its ability to create a well-known brand name.
• The company is subject to risks related to potential safety issues with its products.

Future Outlook

The company expects that the reverse stock split will increase the closing bid price of its common stock above the $1.00 per share requirement, allowing it to maintain its listing on the Nasdaq Capital Market. The company also plans to continue developing and marketing its men's health and wellness products.

Management Comments

• The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. This action is often seen in the biotechnology and pharmaceutical sectors, where companies may experience volatility in their stock prices due to the nature of their research and development activities. The company is operating in the men's health and wellness sector, which is a growing market.

Comparison to Industry Standards

• Many companies facing similar delisting threats from Nasdaq have implemented reverse stock splits to regain compliance.
• For example, companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also used reverse stock splits to maintain their Nasdaq listings.
• The 1-for-15 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-50.
• The success of a reverse stock split in maintaining listing depends on the company's ability to improve its financial performance and investor confidence.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain relatively unchanged.
• The reverse stock split is intended to benefit shareholders by maintaining the company's listing on Nasdaq.
• The reverse stock split may impact the trading price of the stock.

Next Steps

• The company will begin trading on a post-split basis on October 16, 2024.
• The company will continue to work towards regaining full compliance with Nasdaq listing requirements.
• The company will continue to develop and market its men's health and wellness products.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, minimum bid price, MGRX, stock split, Mangoceuticals, common stock, listing requirements